• Hypertrophic Cardiomyopathy (HCM)
  • Vaccines: 2023 Year in Review
  • Eyecare
  • Urothelial Carcinoma
  • Women's Health
  • Hemophilia
  • Heart Failure
  • Vaccines
  • Neonatal Care
  • Type II Inflammation
  • Substance Use Disorder
  • Gene Therapy
  • Lung Cancer
  • Spinal Muscular Atrophy
  • HIV
  • Post-Acute Care
  • Liver Disease
  • Biologics
  • Asthma
  • Atrial Fibrillation
  • RSV
  • COVID-19
  • Cardiovascular Diseases
  • Prescription Digital Therapeutics
  • Reproductive Health
  • The Improving Patient Access Podcast
  • Blood Cancer
  • Ulcerative Colitis
  • Respiratory Conditions
  • Multiple Sclerosis
  • Digital Health
  • Population Health
  • Sleep Disorders
  • Biosimilars
  • Plaque Psoriasis
  • Leukemia and Lymphoma
  • Oncology
  • Pediatrics
  • Urology
  • Obstetrics-Gynecology & Women's Health
  • Opioids
  • Solid Tumors
  • Autoimmune Diseases
  • Dermatology
  • Diabetes
  • Mental Health

Payer Considerations Surrounding TRuE-V Studies


Drs. Owens and Rosmarin discuss payer and provider perspectives from the TRuE-V studies.

In the concluding segment of the video discussion on vitiligo, Gary Owens, M.D., and David Rosmarin, M.D., reflect on the evolving perspectives of payers regarding the condition. They highlight the shift in the understanding of vitiligo from being considered a cosmetic concern to being recognized as a chronic autoimmune disease that necessitates coverage. The introduction of ruxolitinib as a topical therapy for vitiligo in 2022 prompted payers to develop new policies, many of which now consider vitiligo as an autoimmune or immune disorder of the skin.

The experts discuss the significance of evidence-based collaboration between payers and providers in making policy decisions. They emphasize the responsibility of providers to use medicines responsibly, balancing the benefits for patients with the associated costs. The discussion stresses the importance of continued use of ruxolitinib beyond the initial treatment phases, highlighting its meaningful and sustained impact on patients, as evidenced by the TRuE-V primary study and long-term extension.

Dr. Rosmarin, one of the experts, acknowledges the encouraging shift in payer perspectives, with many now allowing ruxolitinib cream as a first-line treatment or after the use of corticosteroids or calcineurin inhibitors. He emphasizes the need for precise documentation, particularly regarding non-segmental vitiligo, which is the predominant type. The pair touch upon the relevance of real-world outcomes, suggesting the possibility of conducting further studies in the future to provide a comprehensive understanding of the long-term effects of ruxolitinib on patients with vitiligo.

The conversation underscores the importance of recognizing vitiligo as a legitimate medical condition, with the potential for significant impacts on patients’ quality of life. The experts express optimism about the evolving landscape of vitiligo treatment and emphasize the need for continued research and collaboration between stakeholders to ensure comprehensive and effective care for patients.

In their closing remarks, they express gratitude to the audience for their engagement and participation throughout the discussion, leaving the viewers with a sense of optimism for the future of vitiligo treatment and research. The experts encourage further exploration and research in the field to continue improving the understanding and management of the condition.

Video synopsis is AI-generated and reviewed by Managed Health Care Executive editorial staff.

Related Videos
Video 9 - "Denial of Coverage in Fertility Care"
Video 8 - "Risks of Miscarriage and Multiple Births Associated with Fertility Care"
Video 7 - "Fertility Preservation: Egg Freezing Versus Embryo Freezing"
Video 6 - "Family Building Costs, Barriers, and Dropout Rates Associated with Fertility Care"
Video 5 - "Closing Payer Gaps and Improving Fertility Care Access"
Video 4 - "Increasing Employer Coverage and Maximizing Fertility Benefits "
Video 5 - "Relevance of NUTURE Study Findings for Patients, Payers, Providers"
Video 3 - "Improving IVF Success Rates & Utilizing AI in Fertility Health Care"
Video 2 - "Holistic Fertility Management and Payer Collaboration"
Video 5 - "Relevance of NUTURE Study Findings for Patients, Payers, Providers"
© 2024 MJH Life Sciences

All rights reserved.